Anzeige
Mehr »
Login
Freitag, 24.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ETCF | ISIN: CNE100006624 | Ticker-Symbol: R9Z
Frankfurt
24.01.25
15:29 Uhr
0,610 Euro
+0,035
+6,09 %
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC Chart 1 Jahr
5-Tage-Chart
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,6100,70520:55

Aktuelle News zur IMMUNEONCO BIOPHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12:43IMMUNEONCO-B (01541): ARTICLES OF ASSOCIATION1
12:39IMMUNEONCO-B (01541): AMENDMENTS TO THE ARTICLES OF ASSOCIATION1
13.01.IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB/II CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH CHEMOTHERAPY FOR THE ...-
10.01.IMMUNEONCO-B (01541): SUPPLEMENTAL ANNOUNCEMENT - DISCLOSEABLE TRANSACTION IN RELATION TO THE DISPOSAL OF A SUBSIDIARY2
IMMUNEONCO BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln
09.01.IMMUNEONCO-B (01541): CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG1
30.12.24IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTION - DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY1
17.12.24IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF NMOSD1
28.11.24IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN-
28.11.24IMMUNEONCO-B (01541): COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE3
20.11.24IMMUNEONCO-B (01541): PLACING OF NEW H SHARES UNDER GENERAL MANDATE1
18.11.24IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM03061
13.11.24IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIALS OF IMM27M-
12.11.24IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE III CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH AZACITIDINE ...-
25.10.24IMMUNEONCO-B (01541): INSIDE INFORMATION - PROPOSED PARTICIPATION IN THE H SHARE FULL CIRCULATION PROGRAMME BY THE COMPANY-
24.10.24IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF SLE1
14.10.24IMMUNEONCO-B (01541): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS1
14.10.24IMMUNEONCO-B (01541): (1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR1
30.09.24IMMUNEONCO-B (01541): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS-
30.09.24IMMUNEONCO-B (01541): (1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR-
27.09.24IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTION - SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT-
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1